PharmaMar

Companies, Relevant News Item 7th November 2025

Pharmamar receives $10 million for reaching Yondelis licence agreement commercial milestone in US

Alphavalue/ Divacons | The biopharmaceutical company received a payment of $10 million from Janssen Products LP, a subsidiary of Johnson & Johnson. This payment comes upon reaching a commercial milestone related to the Yondelis (trabectedin) licence agreement in the United States. The payment stems from the August 2019 licence agreement, under which Janssen has exclusive rights to market and distribute Yondelis in the US market. Janssen has exclusive commercial rights…

Companies 16th October 2025

Pharmamar receives $50 million from Jazz Pharma for approval of Zepzelca + Tecentriq combo treatment for small cell lung cancer

Bankinter | The payment corresponds to the FDA’s full approval on 2 October of the Zepzelca + Tecentriq (Roche) combination as a first-line maintenance treatment for adults with advanced small cell lung cancer whose disease has not progressed after first-line induction treatment with atezolizumab, carboplatin and etoposidei. Jazz Pharma is the exclusive licensee of Zepzelca for the US. Bankinter’s opinion: Positive news, despite which the stock fell yesterday, marking eight…

Companies 3rd October 2025

FDA approves Zepzelca (Pharma Mar) + Tecentriq (Roche) combination therapy for treating lung cancer

Bankinter | The FDA has authorised the combination therapy as a first-line maintenance treatment for adults with advanced small cell lung cancer, following platinum-based therapy. Bankinter analysis team’s view: Positive news, Zepzelca was approved as a second-line treatment, now it moves to first-line and maintenance, making it the first choice for oncologists. This approval should be reflected in an increase in royalty income, direct sales of the drug and sales…

Companies 18th September 2025

PharmaMar’s capital set at €10.8 million after reduction, divided into 18 million shares with unit value of €0.60

Link Securities | PharmaMar (PHM) informed the National Securities Market Commission that, in relation to the execution of the capital reduction through the redemption of treasury shares announced on 30 July 2025, the deed of capital reduction (and consequent amendment to the articles of association) of PHM for an amount of €133,336.80 through the redemption of 222,228 treasury shares with a par value of €0.60 each has been registered in…

Relevant News Item 7th March 2025

JPMorgan Chase acquires 3.12% stake in Pharmamar, valued at €56.8 million

Link Securities | The largest US bank yesterday notified the National Securities Market Commission (CNMV) of a 3.12% stake in the bio-pharmaceutical company Pharmamar. JPMorgan Chase, which reached this threshold last Monday, owns this package directly in shares (2.54%) and the rest (0.57%) through financial instruments (equity swap). With this operation, carried out through different companies and investment funds, this stake would be valued at €56.8 million. Other PharmaMar shareholders,…

Companies, Ibex, Spanish economy 30th September 2022

PharmaMar to liquidate its susidiary Genómica; losses equivalent to -3.5% of NAP

Bankinter | PharmaMar has abandoned Genómica, which will be liquidated. Its fully-owned subsidiary’s main business is molecular diagnostics, mainly via the development and commercialisation of detection kits. In 2021, this affiliate clocked up sales of 5.2 million euros (2.2% of the total), NAP of -3.2 million (vs +92.9 million for the group) and free cash flow of -3.2 million (+44.1 million euros for the group). Bankinter analyst team’s view: Positive news….

Ibex, Markets, Spanish economy 24th September 2020

PharmaMar Debuts This Week In An Ibex With 34 Stocks

On Monday, PharmaMar joined the Ibex 35, the main Spanish stock market index. It will will be composed of 34 stocks until October 19th, following the exclusion of MásMóvil after Lorca Telecom Bidco’s takeover bid. The Ibex 35’s Technical Advisory Committee unexpectedly announced on 10 September that PharmaMar would replace Ence in that index. Since then, the company’s share price has risen by more than 17% to 103.8 euros at last Friday’s close, recovering its July levels.

Ibex, Markets 17th March 2020

Pharmamar confirms Positive Results For Aplidin To Combat Coronavirus

PharmaMar’s shares were trading slightly lower, down 0.20%, at midday today. However that is following a rebound of 33% on Friday, making it the best performing stock on the Spanish stock market. This was after the company announced positive results from studies on Aplidin to combat the coronavirus. As a result, it will ask for tests to be carried out on infected patients.